Contents: Message/R.A. Mashelkar. Introduction/Arun P. Kulshreshtha. I. Global drugs and pharmaceutical sector—situation analysis: 1. Strategy for discovering new therapeutics in developing countries/R. Kumar. 2. Drugs and pharmaceutical sector in NAM countries: implications of WTO and TRIPS/Veena Jha. 3. Current and emerging horizons in global drugs and pharmaceutical sector/Rama Mukherjee. II. Discovery, design and development of Investigative New Drugs (INDs) current trends: 4. Founder's day lecture—new drugs development: an Indian success story/Venkateswerlu. III. Medicinal plants and traditional drugs new precursors for INDs: 5. Potential of medicinal plants as a source for new drugs development/Tuley De Silva. 6. Modern techniques of screening natural products for drug discovery/Mark Butler. 7. Lead optimisation for INDs HIV protease inhibitors: from peptidomimetics to cyclic urease/Javed Iqbal. IV. Tools of automation for rational drug discovery: 8. Structure-activity studies through computer aided modelling/A.K. Saxena. 9. Parallel synthesis and combinatorial libraries/S. Raghavan. 10. Rapid screening of combinatorial libraries/C. Sesagiri Rao. V. Process technologies for bulk drugs: recent trends and innovations (Status of bulk drug processing): 11. Chemistry of important unit processes in the manufacture of bulk drugs and intermediates/A.V. Rama Rao. 12. Clean process options: technological challenges/A.A. Khan. VI. SMEs in bulk drug sector: technological upgradation for global competitiveness: 13. Cluster servicing approach for technology transfer to SMEs: an Indian case study/K.V. Raghavan and M. Hari Babu. 14. Proactive government policies for sustainable growth under a competitive regime/Zafrullah Chowdhury. VII. Quality management in drugs and pharmaceutical sector: (Advance in instrumental methods for bulk drug characterisation): 15. New Drug development: pharmacological screening and preclinical toxicity/P. V. Diwan. 16. Clinical evaluation non-invasive clinical pharmacodynamic methods in evaluation of drug effects/Naidu. 17. Regulatory aspects of drugs and pharmaceuticals: trends and challenges/M. Venkateswarlu. VIII. Fingerprinting of herbal drugs: 18. Fingerprinting of pharmacopoeia for herbal drugs/I. Sanjeeva Rao. 19. Good manufacturing practices in drug industry/P.S. Ramanathan. 20. Drug master files/R. Nageswara Rao. IX. Country status reports: 21. Egypt: current standing of drugs and pharmaceuticals industry. 22. India: drugs and pharmaceuticals—a macro view. 23. Indonesia: developing pharmaceuticals suitable for Indonesian pharmaceutical industries. 24. Iraq: status of the development of drugs and pharmaceuticals including R&D. 25. Malaysia: research and development in herbal medicine towards commercialisation of herbal preparation/drug and the herbal medicine industry. 26. Mauritius: drugs and pharmaceutical industry. 27. Nepal: current status of drugs and pharmaceutical industries. 28. Syria: a national report on the current status of drugs and pharmaceuticals industry. 29. Zambia: country status report. Recommendations. Resolution adopted on development in drugs and pharmaceutical technology, India. Declaration on the trips agreement and public health, WTO, Doha.
"This publication deals with the problems on the development of new medicines and herbal formulations from natural products and traditional drugs, technology transfer in bulk drugs manufacture through horizontal or vertical mechanism preferably through joint venture between the companies in the developing world, quality management R&D on tropical diseases, bio-evaluation of drug molecules (in vitro and in vivo), provision and implications of TRIPS for drugs, manufacturing facilities and standards and modern methods of screening of natural products for developing new bioactives. Status of the development of drugs and pharmaceuticals in some of the developing countries, viz., Bangladesh, Egypt, India, Iraq, Indonesia, Malaysia, Mauritius, Nepal, Syria and Zambia is also included in the publication." (jacket)
